Syros Pharmaceuticals (SYRS)
(Delayed Data from NSDQ)
$6.52 USD
+0.38 (6.19%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $6.55 +0.03 (0.46%) 6:32 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Syros Pharmaceuticals, Inc. [SYRS]
Reports for Purchase
Showing records 201 - 220 ( 222 total )
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
"Festina Lente"; Initiating with Neutral and $16 PT
Provider: Roth Capital Partners, Inc.
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
The Brave New World of AML
Provider: Roth Capital Partners, Inc.
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
"Festina Lente"; Initiating with Neutral and $15 PT
Provider: Roth Capital Partners, Inc.
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
Biotechnology - ESMO ''17 Abstract Roundup and Schedule for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
2Q, Ticking PT to $25 as Ph 2 SY-1425 Readout Nears
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
KOL Feedback on Tamibarotene in AML is Cautious; Reit Neutral - $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
1Q, Ph 2 SY-1425 Data Next Half Could Establish Proof-of- Concept in Multiple AML/MDS Subpopulations, Reiterate OP
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
4Q/FY16, SYRS Looks Attractive with Major Pipeline Catalysts This Year, Reiterate OUTPERFORM and Increasing PT to $22
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
Additional ASH Updates for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
ASH 2016: Additional Abstracts and Sessions of Interest
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
3Q, Well Capitalized to Advance Pipeline Forward, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Unclassified
2Q, SY-1425 Ph 2 Study Enrollment Initiated, Reiterate OP
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D